Latest news with #LarryPowalisz
Yahoo
16-05-2025
- Business
- Yahoo
CORRECTION FROM SOURCE: Adia Nutrition Inc. Successfully Uplists to OTCQB Venture Market in Record-Breaking Six Weeks and Completes SEC Rule 15c2-11 Compliance
This release corrects and replaces the press release issued by Adia Nutrition Inc., on May 16, 2025, at 8:09 am EDT. Winter Park, Florida--(Newsfile Corp. - May 16, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine and nutritional wellness, proudly announces its successful uplisting from the OTC Pink Sheets to the OTCQB Venture Market, effective today. This milestone, achieved in an unprecedented six weeks from the filing date of April 2nd, 2025, alongside the completion of SEC Rule 15c2-11 compliance, reinforces Adia's commitment to transparency, investor accessibility, and delivering on its promises with remarkable speed. OTCQB Uplisting To view an enhanced version of this graphic, please visit: The OTCQB uplisting process, which typically takes companies an average of 12-16 weeks from filing to approval, was executed by Adia Nutrition with exceptional efficiency. This rapid timeline-less than half the industry norm-demonstrates the company's operational excellence and close collaboration with OTC Markets Group, following an independent audit with Astra Audit and Advisory LLC on April 1, 2025. The completion of SEC Rule 15c2-11 compliance is a pivotal achievement, ensuring Adia's financial information is publicly available and meets stringent transparency standards. This rule requires broker-dealers to review and maintain current issuer information before quoting securities, enhancing investor confidence and enabling broader market participation. By satisfying 15c2-11, Adia Nutrition strengthens its credibility, facilitates trading liquidity, and positions itself as a trusted investment opportunity in the regenerative medicine sector. "Uplisting to OTCQB in six weeks and completing 15c2-11 compliance reflect our relentless focus on execution and transparency," said Larry Powalisz, CEO of Adia Nutrition Inc. "We promised our shareholders enhanced visibility, liquidity, and trust, and we've delivered-faster than most. This is yet another goal we set and achieved swiftly, paving the way for our continued growth and our ultimate vision of a Nasdaq Small Cap listing." The OTCQB Venture Market and 15c2-11 compliance elevate Adia Nutrition's ability to showcase its pioneering umbilical cord stem cell therapies and premium nutritional products to a wider investor base. This uplisting follows a series of rapid accomplishments, including the removal of the shell risk designation and the opening of its first Florida clinic for regenerative therapies, solidifying Adia's track record of setting ambitious targets and surpassing them. Adia Nutrition remains dedicated to revolutionizing healthcare through its medical division, specializing in umbilical cord stem cell (UCB-SC) therapies, and its supplement division, delivering premium, organic products. The company invites investors and stakeholders to join its journey as it expands its clinic network and drives innovation. For questions, inquiries or further information, please contact Larry Powalisz at ceo@ or 321-788-0850. About ADIA Nutrition Inc.:Adia Nutrition Inc. (OTCQB: ADIA) is a publicly traded company dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Website: Website: (X): @ADIA_Nutrition Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-05-2025
- Business
- Yahoo
CORRECTION FROM SOURCE: Adia Nutrition Inc. Successfully Uplists to OTCQB Venture Market in Record-Breaking Six Weeks and Completes SEC Rule 15c2-11 Compliance
This release corrects and replaces the press release issued by Adia Nutrition Inc., on May 16, 2025, at 8:09 am EDT. Winter Park, Florida--(Newsfile Corp. - May 16, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine and nutritional wellness, proudly announces its successful uplisting from the OTC Pink Sheets to the OTCQB Venture Market, effective today. This milestone, achieved in an unprecedented six weeks from the filing date of April 2nd, 2025, alongside the completion of SEC Rule 15c2-11 compliance, reinforces Adia's commitment to transparency, investor accessibility, and delivering on its promises with remarkable speed. OTCQB Uplisting To view an enhanced version of this graphic, please visit: The OTCQB uplisting process, which typically takes companies an average of 12-16 weeks from filing to approval, was executed by Adia Nutrition with exceptional efficiency. This rapid timeline-less than half the industry norm-demonstrates the company's operational excellence and close collaboration with OTC Markets Group, following an independent audit with Astra Audit and Advisory LLC on April 1, 2025. The completion of SEC Rule 15c2-11 compliance is a pivotal achievement, ensuring Adia's financial information is publicly available and meets stringent transparency standards. This rule requires broker-dealers to review and maintain current issuer information before quoting securities, enhancing investor confidence and enabling broader market participation. By satisfying 15c2-11, Adia Nutrition strengthens its credibility, facilitates trading liquidity, and positions itself as a trusted investment opportunity in the regenerative medicine sector. "Uplisting to OTCQB in six weeks and completing 15c2-11 compliance reflect our relentless focus on execution and transparency," said Larry Powalisz, CEO of Adia Nutrition Inc. "We promised our shareholders enhanced visibility, liquidity, and trust, and we've delivered-faster than most. This is yet another goal we set and achieved swiftly, paving the way for our continued growth and our ultimate vision of a Nasdaq Small Cap listing." The OTCQB Venture Market and 15c2-11 compliance elevate Adia Nutrition's ability to showcase its pioneering umbilical cord stem cell therapies and premium nutritional products to a wider investor base. This uplisting follows a series of rapid accomplishments, including the removal of the shell risk designation and the opening of its first Florida clinic for regenerative therapies, solidifying Adia's track record of setting ambitious targets and surpassing them. Adia Nutrition remains dedicated to revolutionizing healthcare through its medical division, specializing in umbilical cord stem cell (UCB-SC) therapies, and its supplement division, delivering premium, organic products. The company invites investors and stakeholders to join its journey as it expands its clinic network and drives innovation. For questions, inquiries or further information, please contact Larry Powalisz at ceo@ or 321-788-0850. About ADIA Nutrition Inc.:Adia Nutrition Inc. (OTCQB: ADIA) is a publicly traded company dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Website: Website: (X): @ADIA_Nutrition Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-05-2025
- Business
- Yahoo
Adia Nutrition Inc. Files for OTCQB Uplisting with OTC Markets, Emphasizing OTC-Handled 15c2-11 for Transparency and Investor Reach
Winter Park, Florida--(Newsfile Corp. - May 16, 2025) - Adia Nutrition Inc. (OTC Pink: ADIA), a leader in regenerative medicine and nutritional wellness, proudly announces that it has officially filed with OTC Markets Group for uplisting to the OTCQB Venture Market. This filing follows the successful completion of an independent audit with Astra Audit and Advisory LLC on April 1, 2025, marking a significant milestone in the company's commitment to enhancing visibility, liquidity, and shareholder value through its innovative stem cell therapies and premium nutritional products. As part of this uplisting process, OTC Markets will handle Adia Nutrition's Form 15c2-11, a critical step under SEC regulations that enables broker-dealers to quote the company's securities. By having OTC Markets facilitate this streamlined review, Adia benefits from a more efficient path to public quotation compared to traditional FINRA filings. This process ensures current financial and operational information is publicly available, boosting transparency and investor confidence. The 15c2-11 completion will also enhance market maker participation, improving trading efficiency, liquidity, and price discovery—key advantages as Adia transitions to the OTCQB's higher reporting standards and broader investor reach. OTCQB Up ListingTo view an enhanced version of this graphic, please visit: Additionally, Adia Nutrition has requested the Non-Objecting Beneficial Owners (NOBO) list, a strategic move to strengthen shareholder engagement. Obtaining the NOBO list allows the company to directly communicate with street-name shareholders who do not object to sharing their contact details, bypassing intermediaries like brokers. This direct access enhances Adia's ability to share updates on its pioneering work—such as Umbilical Cord Stem Cell (UCB-SC) therapies and Autologous Hematopoietic Stem Cell Transplantation (aHSCT)—while building closer ties with investors and potentially increasing participation in corporate actions like voting or investment opportunities. "We're thrilled to take this next step toward the OTCQB," said Larry Powalisz, CEO of Adia Nutrition Inc. "Filing for uplisting, leveraging OTC Markets for our 15c2-11, and requesting the NOBO list reflect our focus on transparency and growth. These moves not only elevate our market presence but also connect us more directly with the investors who believe in our mission to transform healthcare through stem cell innovation and nutritional excellence." With this filing, Adia Nutrition is poised to capitalize on the OTCQB's benefits, including greater market credibility and access to a wider investor base, as it continues to expand its network of clinics and advance its science-backed solutions. The company remains on track with its broader roadmap toward a potential Nasdaq Small Cap listing, reinforcing its position as a pioneer in regenerative medicine. For questions, inquiries or further information, please contact Larry Powalisz at ceo@ or 321-788-0850. About ADIA Nutrition Inc.:Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Website: Website: (X): @ADIA_Nutrition Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise. To view the source version of this press release, please visit
Yahoo
14-04-2025
- Business
- Yahoo
Adia Nutrition Inc. Files for OTCQB Uplisting with OTC Markets, Emphasizing OTC-Handled 15c2-11 for Transparency and Investor Reach
Winter Park, Florida--(Newsfile Corp. - April 14, 2025) - Adia Nutrition Inc. (OTC Pink: ADIA), a leader in regenerative medicine and nutritional wellness, proudly announces that it has officially filed with OTC Markets Group for uplisting to the OTCQB Venture Market. This filing follows the successful completion of an independent audit with Astra Audit and Advisory LLC on April 1, 2025, marking a significant milestone in the company's commitment to enhancing visibility, liquidity, and shareholder value through its innovative stem cell therapies and premium nutritional products. As part of this uplisting process, OTC Markets will handle Adia Nutrition's Form 15c2-11, a critical step under SEC regulations that enables broker-dealers to quote the company's securities. By having OTC Markets facilitate this streamlined review, Adia benefits from a more efficient path to public quotation compared to traditional FINRA filings. This process ensures current financial and operational information is publicly available, boosting transparency and investor confidence. The 15c2-11 completion will also enhance market maker participation, improving trading efficiency, liquidity, and price discovery-key advantages as Adia transitions to the OTCQB's higher reporting standards and broader investor reach. Additionally, Adia Nutrition has requested the Non-Objecting Beneficial Owners (NOBO) list, a strategic move to strengthen shareholder engagement. Obtaining the NOBO list allows the company to directly communicate with street-name shareholders who do not object to sharing their contact details, bypassing intermediaries like brokers. This direct access enhances Adia's ability to share updates on its pioneering work-such as Umbilical Cord Stem Cell (UCB-SC) therapies and Autologous Hematopoietic Stem Cell Transplantation (aHSCT)-while building closer ties with investors and potentially increasing participation in corporate actions like voting or investment opportunities. "We're thrilled to take this next step toward the OTCQB," said Larry Powalisz, CEO of Adia Nutrition Inc. "Filing for uplisting, leveraging OTC Markets for our 15c2-11, and requesting the NOBO list reflect our focus on transparency and growth. These moves not only elevate our market presence but also connect us more directly with the investors who believe in our mission to transform healthcare through stem cell innovation and nutritional excellence." With this filing, Adia Nutrition is poised to capitalize on the OTCQB's benefits, including greater market credibility and access to a wider investor base, as it continues to expand its network of clinics and advance its science-backed solutions. The company remains on track with its broader roadmap toward a potential Nasdaq Small Cap listing, reinforcing its position as a pioneer in regenerative medicine. For questions, inquiries or further information, please contact Larry Powalisz at ceo@ or 321-788-0850. About ADIA Nutrition Inc.:Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Website: Website: (X): @ADIA_Nutrition Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise. To view the source version of this press release, please visit
Yahoo
07-04-2025
- Business
- Yahoo
Adia Nutrition Inc. Completes Independent Audit with Astra Audit and Advisory LLC., Prepares to File for OTCQB Uplisting
Winter Park, Florida--(Newsfile Corp. - April 7, 2025) - Adia Nutrition Inc. (OTC Pink: ADIA), a pioneering force in advanced stem cell therapies and nutritional wellness, is proud to announce the successful completion of its independent audit, a crucial milestone that positions the company to file for uplisting to the OTCQB market. This achievement marks a significant step in Adia Nutrition's journey to enhance transparency, build investor confidence, and amplify shareholder value as it continues to revolutionize healthcare through its innovative treatment offerings and wellness solutions. The audit, conducted with precision by Astra Audit and Advisory LLC., a PCAOB-registered auditing firm, was completed efficiently and thoroughly. This process reviewed the company's financials and operations, ensuring compliance with the heightened standards required for the OTCQB tier-a market that demands rigorous reporting and offers greater visibility compared to the OTC Pink market. The successful audit is a testament to Adia Nutrition's commitment to financial integrity as it scales its primary business of providing cutting-edge stem cell therapies, including Umbilical Cord Stem Cell (UCB-SC) treatments and Autologous Hematopoietic Stem Cell Transplantation (aHSCT), to patients nationwide. "We are incredibly excited to reach this point," said Larry Powalisz, CEO of Adia Nutrition Inc. "Completing this audit is a vital step in our uplisting to the OTCQB, reflecting our team's dedication to excellence. This milestone not only strengthens our credibility but also supports our mission to deliver life-changing stem cell therapies to patients while creating value for our shareholders. As we accelerate our growth, we remain committed to advancing regenerative medicine and nutritional wellness with science-backed solutions." The move to OTCQB highlights Adia Nutrition's focus on operational excellence and shareholder trust as it expands its network of clinics delivering advanced stem cell treatments and complementary nutritional products. With the audit finalized, the company is poised to swiftly advance its filing process with the OTC Markets Group, enhancing its market presence and investor appeal. This uplisting will provide greater liquidity and exposure, supporting Adia Nutrition's ambitious goals of treating patients with innovative therapies, such as UCB-SC for inflammation and aHSCT for autoimmune conditions like Multiple Sclerosis, while driving sustainable growth and long-term value for its stakeholders. For questions, inquiries or further information, please contact Larry Powalisz at ceo@ or 321-788-0850. About ADIA Nutrition Inc.:Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Website: Website: (X): @ADIA_Nutrition Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise. To view the source version of this press release, please visit Sign in to access your portfolio
